Loading
JM2 is an experimental peptide from Acomhal Research aimed at the stem-like cells that let glioblastoma grow back. It has not yet been tested in people.
JM2 is the connexin 43 mimetic peptide that Acomhal Research's 2026 National Cancer Institute STTR award describes; the award abstract reports that it reduced glioblastoma stem cell populations in patient-derived models in vivo, and the award funds delivering it by an alphavirus vector. No registered trial was found.
A connexin 43 mimetic peptide that, according to the NIH award abstract, disrupts the interaction of Cx43 with microtubules in glioblastoma stem cells and kills them without affecting normal brain cells.
1.JM2 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"JM2" OR ABSTRACT:"JM2" OR TITLE:"Cx43 mimetic peptide" OR ABSTRACT:"Cx43 mimetic peptide") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about JM2, not a curated reading list.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/